"Actelion is disappointed by the decision and strongly believe there are significant reasons why the Supreme Court should have reviewed the case. The judgment now stands," the Swiss specialty pharma firm said in a statement.
written on 14.03.2014
US court decision stands in Actelion fasudil damages case
